N2 ameliorates neural injury during experimental ischemic stroke via the regulation of thromboxane A2 production.

Abstract

Thromboxane A2 (TXA2) promotes ischemic stroke injury and has strong effects in vascular contraction and vascular endothelial cell dysfunction. Agents that reduce TXA2 production have potential for ameliorating neural injury in ischemic stroke. Thromboxane synthetase (TXS) is essential for TXA2 production, and TXS inhibitors have been developed as drugs for the prevention and treatment of stroke. However, ozagrel, a typical TXS inhibitor currently in clinical use, must be delivered via intravenous injection (I.V.). N2, 4-(2-(1H-imidazol-1-yl) ethoxy)-3-methoxybenzoate, is a potential thromboxane synthetase (TXS) inhibitor, which is being developed as an orally available formulation. The aim of this study was to investigate the effects of N2 on focal cerebral ischemia-reperfusion injury and related mechanisms. Neurological deficits, a Y-maze test and infarct volume were measured to evaluate the effects of N2 post-treatment on middle cerebral artery occlusion (MCAO)-induced ischemia/reperfusion (I/R) injury in rats. Furthermore, the influence of N2 on U46619-induced rat aorta contraction was investigated ex vivo. Moreover, we investigated the protective effects of N2 on rat brain microvessel endothelial cells (RBMECs) in hypoxia/deoxygenating (H/R) induced by Na2S2O4 in vitro. Cell viability and TXA2 biosynthesis were measured by 3-(4, 5-dimethylthiazol-2-yl)- 195 2, 5-diphenyltetrazolium bromide (MTT) and enzyme-linked immunosorbent assay (ELISA) assays, respectively. The results showed that N2 treatment effectively improves performance in neurological deficit and the Y-maze test and reduces the infarct volume in I/R rats. U46619-induced rat aorta contraction was inhibited by N2 ex vivo. Furthermore, N2 incubation improved the morphology of RBMECs, increased cell viability, and suppressed TXA2 production by inhibiting TXS during H/R damage. In summary, this study demonstrated that N2 was neural protective in focal cerebral I/R injury, which might be associated with the effects of N2 on endothelium protection and vascular contraction inhibition. In depth, the mechanisms underlying this phenomenon might be the influence of N2 on TXA2 production targeting TXS.

• Authors: Yi Zhou, Jinru Huang, Wei He, Wenxiang Fan, Weirong Fang, Guangwei He, Qiang Wu, Shaoxing Chu, Yunman Li
• Journal: Pharmacology, biochemistry, and behavior (Pharmacol Biochem Behav) Vol. 124 Pg. 458-65 (Sep 2014) ISSN: 1873-5177 [Electronic] United States
• PMID: 24955863 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• 4-(2-(1H-imidazol-1-yl)ethoxy)-3-methoxybenzoic acid
• Imidazoles
• Neuroprotective Agents
• Thromboxane A2
• Vanillic Acid

Topics

• Animals
• Brain Ischemia (metabolism, pathology)
• Imidazoles (pharmacology)
• In Vitro Techniques
• Male
• Neuroprotective Agents (pharmacology)
• Rats
• Rats, Sprague-Dawley
• Stroke (metabolism, pathology)
• Thromboxane A2 (biosynthesis)
• Vanillic Acid (analogs & derivatives, pharmacology)